VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 187 filers reported holding VAXCYTE INC in Q1 2023. The put-call ratio across all filers is 0.60 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $609,000 | +103.0% | 11,946 | +98.4% | 0.00% | – |
| Q2 2023 | $300,000 | +88.7% | 6,020 | +41.9% | 0.00% | – |
| Q1 2023 | $159,000 | -67.8% | 4,241 | -58.8% | 0.00% | – |
| Q4 2022 | $494,000 | +2252.4% | 10,296 | +1101.4% | 0.00% | – |
| Q3 2022 | $21,000 | +110.0% | 857 | +72.1% | 0.00% | – |
| Q2 2022 | $10,000 | -85.3% | 498 | -82.3% | 0.00% | – |
| Q1 2022 | $68,000 | -67.1% | 2,819 | -67.5% | 0.00% | – |
| Q4 2021 | $207,000 | +66.9% | 8,677 | +77.6% | 0.00% | – |
| Q3 2021 | $124,000 | +87.9% | 4,887 | +67.2% | 0.00% | – |
| Q2 2021 | $66,000 | +32.0% | 2,922 | +16.7% | 0.00% | – |
| Q1 2021 | $50,000 | +257.1% | 2,504 | +377.0% | 0.00% | – |
| Q4 2020 | $14,000 | +27.3% | 525 | +138.6% | 0.00% | – |
| Q3 2020 | $11,000 | +83.3% | 220 | +10.0% | 0.00% | – |
| Q2 2020 | $6,000 | – | 200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $90,711,000 | 29.04% |
| Medicxi Ventures Management (Jersey) Ltd | 3,774,956 | $82,142,000 | 17.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 832,166 | $18,108,000 | 9.12% |
| GREAT POINT PARTNERS LLC | 985,153 | $21,437,000 | 5.14% |
| Kynam Capital Management, LP | 723,781 | $15,749,000 | 4.02% |
| Ghost Tree Capital, LLC | 325,000 | $7,072,000 | 3.68% |
| Frazier Life Sciences Management, L.P. | 1,787,405 | $38,894,000 | 3.67% |
| RA Capital Management | 4,581,203 | $99,687,000 | 2.66% |
| Opaleye Management Inc. | 190,000 | $4,134,000 | 1.86% |
| Soleus Capital Management, L.P. | 370,650 | $8,065,000 | 1.26% |